Unlock future therapies with us
Established in 1925, Croda is the name behind high performance ingredients and technologies in some of the world’s biggest and most successful brands: creating, making, and selling speciality chemicals that are relied on by industries and consumers everywhere. We have a network of over 4,500 passionate and committed employees, working together as one global team across manufacturing sites and offices in 38 countries.
As Croda Pharma, we are committed to empowering biologics delivery. We offer high purity pharmaceutical excipients, world leading vaccine adjuvants, innovative lipids and in-house formulation expertise, making us the ideal partner to navigate drug and vaccine formulation challenges.
Tailored excipient solutions
Create tailored excipient solutions directly in partnership with our scientists.
We work with you to unlock future therapies through developing the next generation of excipients.
Formulate and troubleshoot faster
Tackle your stability challenges with unparalleled purity excipients across all administration routes.
Formulate and troubleshoot faster by working with our scientific experts during your development.
Our technology platforms
We’re committed to investing in the next generation of excipients you need. Our teams work with you to troubleshoot formulations and develop research grade and GMP excipient solutions. Purity is our forte across our multi-compendial, GMP grade materials.
Our portfolio of high purity excipient products and speciality chemistries solve formulation challenges and enhance drug delivery across a variety of administration routes and dosage forms.
Addressing the toughest challenges associated with protein-based therapies, our Super Refined™ range of high purity excipients ensures optimal protein stabilisation for enhanced biologic drug delivery.
Our Avanti lipids range offers innovative lipids of unparalleled purity to solve the stability and delivery issues associated with mRNA for use in vaccines and next-generation therapeutics.
We enable next-generation vaccine development through a diverse portfolio of world-leading vaccine adjuvants, immunomodulators and adjuvant formulations.